|
| 安脑颗粒联合奥氮平、齐拉西酮对女性首发精神分裂症急性激越症状及预后的影响 |
| Effects of acute agitation symptoms and prognosis of An nao granule combined with olanzapine and Ziprasidonefor female first-episode schizophrenia |
| 投稿时间：2020-12-30 修订日期：2020-12-30 |
| DOI： |
| 中文关键词: 安脑颗粒 奥氮平 齐拉西酮 女性 首发精神分裂症 激越症状 睡眠质量 |
| 英文关键词: |
| 基金项目: |
| 摘要点击次数: 570 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 在奥氮平、齐拉西酮基础上,联合安脑颗粒治疗女性精神分裂症患者,观察对患者激越症状的改善作用,并评估对患者预后及睡眠质量的影响。方法 选择本院2018年2月～2019年2月女性精神分裂症患者144例,随机分为对照组和观察组,每组各72例,观察组在对照组患者应用奥氮平、齐拉西酮基础上,给予安脑颗粒进行治疗。分别于治疗前及治疗后不同时间应用Cohen-Mansfield 激越问卷(CMAI))评估患者激越状况,应用阳性和阴性症状量表(PANSS)、中医症候积分评估患者预后,并评估患者睡眠状况。结果 观察组治疗后1周、2周、4周CMAI 评分结果分别为(48.11±2.39)分、(45.37±2.47)分、(42.48±2.76)分,均低于对照组(49.27±2.70)分、(47.06±2.63)分、(45.02±2.81)分,差异有统计学意义(P＜0.05)；观察组治疗后阳性症状、阴性症状、一般精神病理症状及总评分、中医症候积分、SL和AT分别为(13.06±1.94)分、(25.34±2.35)分、(14.37±2.47)分、(46.45±3.48)分、(21.75±2.69)min和(30.52±2.57)min,均低于对照组(15.12±2.12)分、(29.45±2.47)分、(16.03±2.32)分、(52.08±3.25)分、(26.95±2.73)min和(34.28±2.39)min,观察组患者TST、PSQI分别为(495.63±15.19)min和(18.09±1.16)分,均高于对照组(438.64±15.07)min和(16.53±1.08)分,差异有统计学意义(P＜0.05)。结论 与奥氮平、齐拉西酮治疗女性精神分裂症患者比较,联合应用安脑颗粒更能够改善患者激越症状和睡眠质量,患者预后改善更加明显。 |
| 英文摘要: |
| Objective Based on olanzapine and Ziprasidone, give An nao granule treat for female schizophrenia patients ,to observe the improvement of the patients "agitation, and evaluate the impact on the patients" sleep status and prognosis. Methods 144 female schizophrenic patients from February 2018 to February 2019 in our hospital were randomly divided into control group and observation group, with 72 cases in each group. The observation group was given An nao granule for treatment based on olanzapine and Ziprasidone in the control group.Cohen-Mansfield Agitation Questionnaire (CMAI) was used to assess the agitation status of patients before treatment and at different times after treatment. The positive and negative symptom scale (PANSS) , TCM Syndrome Score were used to assess the prognosis of patients, and the sleep status of patients were evaluated.Results CMAI scores of the observation group after 1.2 4 week were (48.11±2.39) points, (45.37±2.47) points, (42.48±2.76) points,lower than the control group (49.27±2.70) points. (47.06±2.63) points and (45.02±2.81) points, the difference was statistically significant (P <0.05).Positive symptoms, negative symptoms, general psychopathological symptoms and total score,TCM Syndrome Score, SL and AT of the observation group after treatment were (13.06±1.94) points, (25.34±2.35) points, (14.37±2.47) points, (46.45±3.48) points,(6.38±0.74)points,(21.75±2.69) min and (30.52±2.57) min,lower than the control group (15.12±2.12 )points, (29.45±2.47) points, (16.03±2.32) points, (52.08±3.25) points, (7.96±0.87)points, (26.95±2.73) min and (34.28±2.39) min, TST and PSQI of the observation group were (495.63±15.19) ) Min and (18.09±1.16) points are higher than the control group (438.64±15.07) min and (16.53±1.08) points, the difference is statistically significant (P<0.05). onclusion Compared with olanzapine and Ziprasidone for the treatment of female schizophrenia patients, combined with An nao granule can improve the patient"s agitation symptoms and sleep quality. The patient"s prognosis is more obvious. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
